| Literature DB >> 24614678 |
Laura Wiley1, Deepthi Ashok1, Carmen Martin-Ruiz1, Duncan C S Talbot2, Joanna Collerton1, Andrew Kingston1, Karen Davies1, Patrick F Chinnery3, Michael Catt1, Carol Jagger1, Thomas B L Kirkwood1, Thomas von Zglinicki1.
Abstract
Reliable and valid biomarkers of ageing (BoA) are needed to understand mechanisms, test interventions and predict the timing of adverse health events associated with ageing. Since increased reactive oxygen species (ROS) production and mitochondrial dysfunction are consequences of cellular senescence and may contribute causally to the ageing of organisms, we focused on these parameters as candidate BoA. Superoxide levels, mitochondrial mass and mitochondrial membrane potential in human peripheral blood mononuclear cells (PBMCs) and subpopulations (lymphocytes and monocytes) were measured in participants from the Newcastle 85+ study, a population-based study of the very old (aged 85 years and older). The intra- and inter-assay precision expressed as coefficient of variation (CV) for all parameters was acceptable (3% to 12% and 5 to 22% respectively). All parameters were stable in the short-term (1 week interval) in a sample of control individuals in the PBMCs and lymphocyte subpopulation, however they were unstable in the monocyte subpopulation; this rendered monocytes unreliable for further analysis. There was a significant association between superoxide levels and mitochondrial mass (positive in lymphocytes, p = 0.01) and between superoxide levels and mitochondrial membrane potential (negative in PBMCs, p = 0.01; positive in lymphocytes, p = 0.05). There were also significant associations between superoxide levels and mitochondrial parameters with other markers of oxidative stress-induced cellular senescence (p≤0.04), however some were in the opposite direction to expected. No associations were found between the measured parameters and age-related outcomes, including cognitive impairment, disability, co-morbidity and survival - questioning the validity of these parameters as candidate BoA in the very old.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24614678 PMCID: PMC3948743 DOI: 10.1371/journal.pone.0091005
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1ROS production from dysfunctional mitochondria as the driving force of cellular ageing.
ROS accelerates the onset of replicative senescence by increasing the rate of telomere shortening [42], [43] as well as feeding into a continuous DNA damage response that sustains the accumulation of inflammatory mediators as part of the senescence-associated secretory phenotype (SASP), and mitochondrial dysfunction, defined as enhanced production of superoxide together with (frequently) increased mitochondrial mass and decreased mitochondrial membrane potential. This maintains an irreversible state of persistent damage in senescent cells [22], [44]. The subsequent dysregulation of physiological function contributes to age-related pathology and/or carcinogenesis [45], [46].
Descriptive statistics of biomarker measurements.
| Descriptives | |||||
| Biomarker | Mean | SE | Median | IQR | n |
|
| |||||
| Superoxide levels (AU) | |||||
|
| 37.99 | 1.15 | 33.94 | 20.17 | 248 |
|
| 29.39 | 1.11 | 25.39 | 20.81 | 248 |
| Mitochondrial mass (AU) | |||||
|
| 43.35 | 0.89 | 41.69 | 19.99 | 341 |
|
| 51.43 | 1.75 | 44.6 | 32.06 | 341 |
| Mitochondrial membrane potential (AU) | |||||
|
| 3.16 | 0.07 | 2.86 | 0.98 | 347 |
|
| 4.24 | 0.10 | 3.85 | 2.00 | 347 |
|
| |||||
| 8-Iso Prostaglandin F2α (ng/ml) | 2.69 | 0.16 | 1.49 | 2.08 | 379 |
|
| |||||
| Telomere length (bp) | 2825.03 | 37.55 | 2715.77 | 1057.17 | 430 |
|
| |||||
| DNA damage (%) | 46.22 | 0.91 | 47.26 | 29.65 | 431 |
| DNA repair (%) | 48.47 | 1.35 | 46.24 | 47.27 | 431 |
|
| |||||
| CD27-/RO- CD4 T lymphocytes (%) | 4.10 | 0.35 | 1.46 | 3.32 | 429 |
| CD27-/RO- CD8 T lymphocytes (%) | 24.66 | 0.85 | 21.81 | 25.69 | 403 |
|
| |||||
| Il-6 (pg/ml) | 539.55 | 133.85 | 10.25 | 31.43 | 430 |
| TNF-α (pg/ml) | 37.64 | 9.86 | 2.55 | 4.42 | 430 |
| hsCRP (mg/l) | 5.63 | 0.63 | 2.40 | 3.70 | 434 |
|
| |||||
| Hand grip strength (kg) | 17.06 | 0.35 | 16.10 | 9.03 | 453 |
| TUG (seconds) | 21.52 | 0.94 | 17.09 | 12.19 | 402 |
| FEV1 (l)P1 | 144.55 | 1.94 | 137.00 | 71.75 | 776 |
| Systolic blood pressure (mmHg) | 143.04 | 0.96 | 144.00 | 28.00 | 462 |
| Haematocrit (%) | 0.39 | 0.00 | 0.39 | 0.05 | 427 |
| Haemoglobin (g/dl) | 12.90 | 0.07 | 13.00 | 1.70 | 427 |
| Red blood cells (x 1012/l) | 4.25 | 0.02 | 4.25 | 0.62 | 427 |
| Free T3 (pmol/l) | 4.39 | 0.03 | 4.40 | 0.80 | 426 |
| Vitamin D (nmol/l)P1 | 45.36 | 0.94 | 39.00 | 37.00 | 778 |
| NT-pro BNP (pg/ml) | 848.21 | 89.05 | 514.00 | 791.75 | 124 |
(SE: Standard error, IQR: Interquartile range, n: Number of participants, P1Baseline (phase 1)).
Superoxide levels, mitochondrial mass and mitochondrial membrane potential in relation to other potential markers of oxidative stress induced cellular senescence.
| Superoxide levels | Mitochondrial mass | Mitochondrial membrane potential | |||||
|
|
|
|
|
|
| ||
|
| r | −0.05 | −0.03 | 0.06 | 0.03 | 0.03 | 0.02 |
| p | 0.45 | 0.65 | 0.34 | 0.64 | 0.62 | 0.77 | |
| n | 216 | 216 | 302 | 302 | 304 | 304 | |
|
| r | 0.11 | 0.08 |
|
|
| 0.04 |
| p | 0.08 | 0.23 |
|
|
| 0.41 | |
| n | 248 | 248 |
|
|
| 345 | |
|
| r | −0.06 | −0.09 | 0.05 | −0.03 | 0.03 | 0.03 |
| p | 0.33 | 0.16 | 0.38 | 0.53 | 0.63 | 0.64 | |
| n | 248 | 248 | 341 | 341 | 347 | 347 | |
|
| r |
|
| −0.06 | −0.07 | 0.06 | −0.03 |
| p |
|
| 0.26 | 0.21 | 0.24 | 0.59 | |
| n |
|
| 341 | 341 | 347 | 347 | |
|
| r | −0.11 | −0.07 | 0.08 | 0.08 | 0.04 | −0.01 |
| p | 0.09 | 0.31 | 0.15 | 0.13 | 0.42 | 0.91 | |
| n | 246 | 246 | 339 | 339 | 344 | 344 | |
|
| r | −0.09 | −0.04 | 0.09 | 0.08 | 0.03 | −0.02 |
| p | 0.17 | 0.57 | 0.12 | 0.14 | 0.62 | 0.75 | |
| n | 237 | 237 | 317 | 317 | 323 | 323 | |
|
| r |
|
| −0.02 | −0.05 | −0.07 |
|
| p |
|
| 0.72 | 0.31 | 0.23 |
| |
| n |
|
| 340 | 340 | 345 |
| |
|
| r |
|
| −0.03 | −0.05 | −0.03 |
|
| p |
|
| 0.60 | 0.33 | 0.58 |
| |
| n |
|
| 340 | 340 | 345 |
| |
|
| r | 0.08 | 0.11 | 0.03 | 0.00 | −0.10 | −0.01 |
| p | 0.19 | 0.08 | 0.56 | 0.94 | 0.05 | 0.81 | |
| n | 248 | 248 | 341 | 341 | 347 | 347 | |
(r: Spearman's correlation coefficient, p: probability, n: number of participants).
Superoxide levels, mitochondrial mass and mitochondrial membrane potential in relation to informative BoA.
| Superoxide levels | Mitochondrial mass | Mitochondrial membrane potential | |||||
|
|
|
|
|
|
| ||
|
| r | 0.01 | 0.00 | −0.02 | −0.05 | −0.06 | −0.01 |
| p | 0.85 | 0.95 | 0.71 | 0.35 | 0.29 | 0.87 | |
| n | 242 | 242 | 336 | 336 | 342 | 342 | |
|
| r | −0.01 | −0.01 | 0.03 | 0.05 | 0.06 | 0.07 |
| p | 0.94 | 0.91 | 0.64 | 0.37 | 0.30 | 0.23 | |
| n | 218 | 218 | 304 | 304 | 312 | 312 | |
|
| r | 0.07 | 0.06 | 0.02 | −0.04 | 0.01 | −0.01 |
| p | 0.29 | 0.32 | 0.77 | 0.49 | 0.85 | 0.83 | |
| n | 244 | 244 | 335 | 335 | 341 | 341 | |
|
| r | 0.02 | −0.02 | 0.07 | 0.09 | 0.01 | 0.01 |
| p | 0.77 | 0.79 | 0.22 | 0.09 | 0.92 | 0.87 | |
| n | 245 | 245 | 338 | 338 | 343 | 343 | |
|
| r | 0.06 | 0.07 | 0.05 | −0.03 | −0.04 | −0.05 |
| p | 0.37 | 0.26 | 0.35 | 0.53 | 0.49 | 0.36 | |
| n | 246 | 246 | 338 | 338 | 343 | 343 | |
|
| r | 0.05 | 0.07 | 0.08 | −0.01 | 0.01 | −0.06 |
| p | 0.44 | 0.25 | 0.16 | 0.81 | 0.82 | 0.29 | |
| n | 246 | 246 | 338 | 338 | 343 | 343 | |
|
| r | 0.08 | 0.12 | 0.10 | 0.05 | −0.03 | −0.08 |
| p | 0.20 | 0.07 | 0.08 | 0.36 | 0.6 | 0.13 | |
| n | 246 | 246 | 338 | 338 | 343 | 343 | |
|
| r | −0.09 | −0.11 | 0.03 | −0.04 | −0.07 |
|
| p | 0.16 | 0.08 | 0.61 | 0.51 | 0.19 |
| |
| n | 246 | 246 | 338 | 338 | 343 |
| |
|
| r | −0.12 |
| −0.01 | −0.05 | −0.10 |
|
| p | 0.06 |
| 0.89 | 0.35 | 0.06 |
| |
| n | 240 |
| 331 | 331 | 338 |
| |
|
| r | −0.10 | −0.19 | −0.09 | −0.17 | −0.10 | 0.11 |
| p | 0.50 | 0.19 | 0.39 | 0.12 | 0.33 | 0.30 | |
| n | 46 | 46 | 85 | 85 | 95 | 95 | |
(r: Spearman's correlation coefficient, p: probability, n: number of participants, P1Phase 1 data).
Association between superoxide levels, mitochondrial mass, mitochondrial membrane potential and age-related outcomes.
| Superoxide levels | Mitochondrial mass | Mitochondrial membrane potential | |||||
|
|
|
|
|
|
| ||
|
| r | 0.00 | 0.01 | −0.03 | 0.01 | 0.02 | 0.07 |
| p | 0.95 | 0.90 | 0.60 | 0.83 | 0.75 | 0.21 | |
| n | 247 | 247 | 339 | 339 | 345 | 345 | |
|
| r | 0.07 | 0.08 | 0.08 | 0.04 | 0.05 | −0.08 |
| p | 0.25 | 0.19 | 0.13 | 0.44 | 0.35 | 0.13 | |
| n | 247 | 247 | 339 | 339 | 345 | 345 | |
|
| r | 0.08 | 0.08 | 0.04 | 0.07 | −0.03 | −0.01 |
| p | 0.20 | 0.25 | 0.46 | 0.22 | 0.55 | 0.90 | |
| n | 239 | 239 | 328 | 328 | 334 | 334 | |
(r: Spearman's correlation coefficient, p: probability, n: number of participants).
Figure 2Association between PBMC superoxide levels, mitochondrial mass, mitochondrial membrane potential and survival.
(Cox regression analysis)